A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 373 participants.

Also called NCT05618808

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 373 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05618808
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Belgium, Bulgaria, Canada, Hungary, Latvia, Lithuania, Poland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05618808. Randomized; no masking; primary purpose treatment. Start 2023-05-24 (actual); primary completion 2024-05-27 (actual). Results posted on 2025-07-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants
Condition
Venous Thromboembolism
Intervention (Drug)
REGN9933
Intervention (Drug)
Enoxaparin
Intervention (Drug)
Apixiban
Lead sponsor
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05618808
Content hash
ad16755f2debb9efd5c6edd4c3a840e1956bc16ddd35ca2a902ad5240aa9f83d